A 17% revenue beat, positive GAAP operating income, and a raised outlook reframe PATH as a durable AI automation compounder – not a speculative recovery story.
Why Humanoid Robotics Is the Most Watched Emerging Theme on Wall Street Right Now
Beyond the weight-loss supercycle, a new class of targeted therapies is driving institutional rotation into mid-cap biotech – and the valuation entry points remain compelling.
NVDA beat hard, guided higher, and still slipped. The market’s reaction might be the most important signal of the quarter.
XLE posted a 37% Q1 surge. But with Brent near $106, a Strait of Hormuz standstill, and the EIA flagging record production shut-ins, the real question isn’t whether energy ran — it’s whether it can hold.
Kevin Warsh just replaced Jerome Powell. Inflation is at 3.8%. The FedWatch Tool is pricing in rate hikes, not cuts. And the S&P 500 is historically expensive. Traders need a framework for what comes next.
